Catalog No.S8014

GW9508 is a potent and selective agonist for FFA1 (GPR40) with pEC50 of 7.32, 100-fold selective against GPR120, stimulates insulin secretion in a glucose-sensitive manner.

Price Stock Quantity  
USD 107 In stock
USD 447 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

GW9508 Chemical Structure

GW9508 Chemical Structure
Molecular Weight: 347.41

Validation & Quality Control

Quality Control & MSDS

Product Information

  • Compare GPR Modulators
    Compare GPR Products

Product Description

Biological Activity

Description GW9508 is a potent and selective agonist for FFA1 (GPR40) with pEC50 of 7.32, 100-fold selective against GPR120, stimulates insulin secretion in a glucose-sensitive manner.
Targets GPR40 [1] GPR120 [1]
IC50 7.32(pEC50) 5.46(pEC50)
In vitro GW9508 is shown to be at least 100-fold selective against 220 other GPCRs, 60 kinases, 63 proteases, seven integrins and 20 nuclear receptors including PPARα, δ and γ (pEC50 4.0, 4 and 4.9, respectively). GW9508 produces a concentration-dependent increase in intracellular Ca2+ concentrations via GPR40 receptor activation and the GPR120 receptor. GW9508 is active as an agonist at both GPR40 and GPR120, it is approximately 100-fold selective for GPR40 with respect to GPR120. GW9508 produces a concentration-dependent increase (pEC50=6.14) in glucose-stimulated insulin secretion at high glucose levels (25 mM). GW9508 dose dependently stimulated insulin secretion in a glucose-sensitive manner in MIN6 cells. Furthermore, GW9508 is able to potentiate the KCl-mediated increase in insulin secretion in MIN6 cells. [1] GW9508 induced hyperpolarization and opening of KATP channels in rat β-cells. [2] GW9508 inhibits CCL17 and CCL5 expression in a pertussis toxin-sensitive manner. GW9508 further suppresses expression of IL-11, IL-24, and IL-33 induced in HaCaT cells by TNF-α and IFN-γ. GW9508 also inhibits CCL5 and CXCL10 production by normal human epidermal keratinocytes. [3]
In vivo
Features The effects of GW9508 on insulin secretion are reversed by GW1100, while linoleic acid-stimulated insulin secretion is partially attenuated by GW1100.

Protocol(Only for Reference)

Kinase Assay: [1]

Measurement of intracellular Ca2+ release HEK-293 cells, stably transfected to express the human macrophage scavenging receptor are maintained in Dulbecco's modified Eagles medium (DMEM; high glucose) containing 10% (v/v) heat-inactivated fetal calf serum. The expression of this receptor by the HEK-293 cells enhances their ability to stick to tissue culture treated plasticware. Cells are harvested using an enzyme-free cell dissociation buffer. Of this solution, 5 ml, is added and allowed to wash over the cells for 30 s. The solution is then removed and the cells return to the incubator for 5 min. Following a gently tapping of the flask the cells are resuspended in media. For GPR40 studies cells are transduced with GPR40 BacMam baculovirus at a multiplicity of infection (MOI) of 25. Control cells are not transduced with virus. The cells are plated at a concentration of 10,000 cells per well in black 384-well clear bottom tissue culture treated plates. The cells are cultured for 24 h at 37°C in a humidified 5% CO2 air environment to allow for protein expression. Subsequently, the medium is removed from the wells and replaced with 40 μl of Calcium-3 dye. The cells are allowed to load with dye for 1 h at 37°C in a cell culture incubator. The plates are then allowed to cool to room temperature for 20 min. All compounds are diluted to appropriate concentrations in Calcium-3 dye. Compounds are added during the assay by the FLIPR3 instrument in 10 μL per well volumes and the wells are read by the instrument every 2 s for 90 s. Antagonist studies are performed in a similar format. Antagonist is added to the well in a 10 μL volume and the plates are incubated at room temperature for 15 min before the second addition of 10 μL per well of an ED80 concentration of agonist.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)


[1] Briscoe CP, et al. Br J Pharmacol, 2006, 148(5), 619-628.

[2] Zhao YF, et al. J Endocrinol, 2008, 198(3), 533-540.

view more

Chemical Information

Molecular Weight (MW) 347.41


CAS No. 885101-89-3
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 69 mg/mL (198.61 mM)
Ethanol 69 mg/mL (198.61 mM)
Water <1 mg/mL
In vivo
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name Benzenepropanoic acid, 4-[[(3-phenoxyphenyl)methyl]amino]-

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related GPR Products

  • LCZ696

    LCZ696, consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. Phase 3.

  • Endoxifen HCl

    Endoxifen HCl, the active metabolite of Tamoxifen, ia a potent and selective estrogen receptor antagonist. Phase 2.

  • Licochalcone A

    Licochalcone A is an estrogenic flavanoid extracted from licorice root, showing antimalarial, anticancer, antibacterial and antiviral activities. Phase 3.

  • GSK1292263

    GSK1292263 is a novel GPR119 agonist, showing potential for the treatment of type 2 diabetes. Phase 2.

  • TAK-875

    TAK-875 is a selective GPR40 agonist with EC50 of 14 nM in human GPR40 expressing CHO cell line, 400-fold more potent than oleic acid.

    Features:More potent at activating hGPR40 than oleic acid.

  • OC000459

    OC000459 is a potent and selective D prostanoid receptor 2 (DP2) antagonist with IC50 of 13 nM. Phase 2.

  • AZD1981

    AZD1981 is a potent, selective CRTh2 (DP2) receptor antagonist with IC50 of 4 nM, showing >1000-fold selectivity over more than 340 other enzymes and receptors, including DP1. Phase 2.

    Features:An orally available selective DP2(CRTh2) receptor antagonist in clinical development for asthma.

  • Enzalutamide (MDV3100)

    Enzalutamide (MDV3100) is an androgen-receptor (AR) antagonist with IC50 of 36 nM in LNCaP cells.

  • Fulvestrant

    Fulvestrant is an estrogen receptor (ER) antagonist with IC50 of 0.94 nM in a cell-free assay.

  • Tamoxifen Citrate

    Tamoxifen Citrate is an antagonist of the estrogen receptor by competitive inhibition of estrogen binding.

Recently Viewed Items

Tags: buy GW9508 | GW9508 supplier | purchase GW9508 | GW9508 cost | GW9508 manufacturer | order GW9508 | GW9508 distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us